Avidity Biosciences, Inc.

RNA

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
AOC 1001 (del-desiran)	Phase 3	DM1	-
AOC-1020	Phase 3	Facioscapulohumeral Muscular Dystrophy	-
AOC 1044	Phase 2	Duchenne Muscular Dystrophy	-
AOC 1001	Phase 2	DM1	-
AOC 1020	Phase 2	FSHD	-
Placebo	Phase 2	DM1	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

March 2026~AOC 1001 (del-desiran)

Primary completion for AOC 1001 (del-desiran) trial (NCT06411288) in DM1

Phase 2

October 2026~AOC 1020

Primary completion for AOC 1020 trial (NCT05747924) in FSHD

Regulatory Approvals

RNA News

RNA